PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.

PD-1 TIGIT Th1 immunity immunosuppression nivolumab and ipilimumab oesophageal adenocarcinoma perioperative surgery

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 25 01 2023
accepted: 11 05 2023
medline: 28 6 2023
pubmed: 26 6 2023
entrez: 26 6 2023
Statut: epublish

Résumé

This timely study assesses the immunosuppressive effects of surgery on cytotoxic Th1-like immunity and investigates if immune checkpoint blockade (ICB) can boost Th1-like immunity in the perioperative window in upper gastrointestinal cancer (UGI) patients. PBMCs were isolated from 11 UGI patients undergoing tumour resection on post-operative days (POD) 0, 1, 7 and 42 and expanded Th1-like immunity was suppressed in expanded PBMCs in the immediate post-operative setting. The frequency of expanded circulating Th1-like cells was significantly decreased post-operatively accompanied by a decrease in IFN-γ production and a concomitant increase in the frequency of expanded regulatory T cells with an increase in circulating levels of IL-10. Interestingly, PD-L1 and CTLA-4 immune checkpoint proteins were also upregulated on expanded Th1-like cells post-operatively. Additionally, the cytotoxic ability of expanded lymphocytes against oesophageal adenocarcinoma tumour cells was abrogated post-surgery. Of note, the addition of nivolumab or ipilimumab attenuated the surgery-mediated suppression of lymphocyte cytotoxicity, demonstrated by a significant increase in tumour cell killing and an increase in the frequency of Th1-like cells and Th1 cytokine production. These findings support the hypothesis of a surgery-mediated suppression in Th1-like cytotoxic immunity and highlights a rationale for the use of ICB within the perioperative setting to abrogate tumour-promoting effects of surgery and ameliorate the risk of recurrence.

Identifiants

pubmed: 37359545
doi: 10.3389/fimmu.2023.1150754
pmc: PMC10288841
doi:

Substances chimiques

Interleukin-10 130068-27-8
Programmed Cell Death 1 Receptor 0
Nivolumab 31YO63LBSN
Ipilimumab 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1150754

Informations de copyright

Copyright © 2023 Davern, Gaughan, O’ Connell, Moran, Mylod, Sheppard, Ramjit, Yun-Tong Kung, Phelan, Davey, Ryan, Butler, Quinn, Howard, Tone, Phoenix, Butt, Lynam-Lennon, Maher, Ravi, Donohoe, Reynolds, Lysaght and Donlon.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int Immunol. 2009 Oct;21(10):1105-11
pubmed: 19737784
J Thorac Dis. 2018 May;10(5):2691-2699
pubmed: 29997931
Br J Surg. 2000 Feb;87(2):236-42
pubmed: 10671934
Cell Metab. 2018 Jan 9;27(1):85-100.e8
pubmed: 29129787
Int J Mol Sci. 2018 Jul 09;19(7):
pubmed: 29987244
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Hepatobiliary Pancreat Dis Int. 2014 Oct;13(5):482-94
pubmed: 25308358
Cancer Lett. 2021 Apr 1;502:84-96
pubmed: 33450360
Front Immunol. 2020 Nov 11;11:587581
pubmed: 33262766
Clin Transl Med. 2020 Jan;10(1):199-223
pubmed: 32508035
Crit Rev Oncol Hematol. 2022 Jul;175:103729
pubmed: 35662586
J Immunother Cancer. 2018 Sep 3;6(1):86
pubmed: 30176921
Onco Targets Ther. 2019 Oct 15;12:8437-8445
pubmed: 31686860
Cancer Res. 2017 Apr 1;77(7):1548-1552
pubmed: 28330928
Expert Opin Biol Ther. 2021 Jun;21(6):697-703
pubmed: 33736560
Front Immunol. 2022 Jan 27;13:823225
pubmed: 35154142
Oncol Lett. 2012 Oct;4(4):625-630
pubmed: 23205074
Cancer Immunol Immunother. 2023 Jan;72(1):55-71
pubmed: 35708739

Auteurs

Maria Davern (M)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

Caoimhe Gaughan (C)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.

Fiona O' Connell (F)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Brendan Moran (B)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Eimear Mylod (E)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Andrew D Sheppard (AD)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.

Sinead Ramjit (S)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Jasmine Yun-Tong Kung (J)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

James J Phelan (JJ)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.

Matthew G Davey (MG)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Eanna J Ryan (EJ)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Christine Butler (C)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Laura Quinn (L)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Claudine Howard (C)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Emily Tone (E)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Eimear Phoenix (E)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Waqas T Butt (WT)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Niamh Lynam-Lennon (N)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.

Stephen G Maher (SG)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.

Narayanasamy Ravi (N)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Claire L Donohoe (CL)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

John V Reynolds (JV)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Joanne Lysaght (J)

Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin, Ireland.

Noel E Donlon (NE)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH